Press Release Archive
-
New Late-Breaking XARELTO® (rivaroxaban) and INVOKANA® (canagliflozin) Data to be Presented at the American College of Cardiology's Annual Scientific Session
-
New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers
-
Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics
-
NEW TREMFYA® (GUSELKUMAB) DATA DEMONSTRATES LONG-TERM SKIN CLEARANCE IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
-
JOHNSON & JOHNSON CONSUMER PRESENTS NEW SCIENTIFIC RESEARCH AT 2018 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING
-
ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
-
ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
-
ZYTIGA® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
-
Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio
-
JANSSEN ENTERS INTO WORLDWIDE COLLABORATION WITH THERAVANCE BIOPHARMA FOR ORAL, PAN-JAK INHIBITOR DRUG CANDIDATE FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE